CClinicalTrials.gg
Sign In
WithdrawnNCT05774392Updated Dec 17, 2025

An Observational Study of Patients With Chronic Kidney Disease

An observational study in Kidney Disease, Chronic and End Stage Kidney Disease, sponsored by Target PharmaSolutions, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Target PharmaSolutions, Inc. · Observational

Why this study was withdrawn
This protocol never enrolled any paticipants
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).

02

Conditions studied

  • Kidney Disease, Chronic
  • End Stage Kidney Disease
03

In context

Renal Insufficiency, Chronic

3,144 studies on the registry are indexed under Renal Insufficiency, Chronic; 704 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

Target PharmaSolutions, Inc. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study will include adults who are being managed for Stage 1-5 CKD or received a transplant for ESKD.

Eligibility criteria

Disease Cohort

Inclusion Criteria:

  • Adult* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface

Exclusion Criteria:

  • Death
  • Manual removal (sponsor or site request)
  • No EHR interface encounter > 3 years

Engaged Cohort

Inclusion Criteria:

  • Adult * patients diagnosed and managed for CKD/ESKD invited to participate
  • Ability to provide written informed consent

Exclusion Criteria:

  • Patient expressed desire to withdraw consent to complete PROs
  • Failure to complete PROs within 24 weeks of initial invitation
  • Greater than 24 months lapse of survey completion after baseline surveys completed
  • Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
0 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Disease Cohort

    Other: Observational

  • Engaged Cohort

    Other: Observational

Interventions

  • OtherObservational

    Observational

06

What researchers measure

Primary outcomes

  1. To characterize the natural history of disease in patients with CKD/ESKD.

    Time frame: 20 Years

  2. To assess safety and effectiveness of CKD/ESKD treatments and treatments for complications of either condition

    Time frame: 20 Years

Secondary outcomes

  1. To evaluate provider management practices in the treatment of patients with CKD/ESKD

    Time frame: 20 Years

  2. To evaluate longitudinal and patient reported outcomes in CKD/ESKD

    Time frame: 20 Years

  3. To select and evaluate quality of care measures for patients with CKD/ESKD

    Time frame: 20 Years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05774392
Lead sponsor
Target PharmaSolutions, Inc.
Responsible party
Sponsor
First posted
Mar 17, 2023
Start date
Apr 2025 (estimated)
Primary completion
Apr 7, 2025
Completion
Apr 7, 2025
Last update
Dec 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Renal Insufficiency, Chronic→

Other studies from this sponsor

Target PharmaSolutions, Inc.

Start the discussion